Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Sign up Log in

MorphoSys AG Investor Presentation 2010

Jul 29, 2010

291_ip_2010-07-29_e1a450c0-1d84-44f2-b7f5-0f79cc74cc3f.pdf

Investor Presentation

Open in viewer

Opens in your device viewer

Fifth Annual Piper Jaffray Europe Conference

London – June 22, 2010

Safe Harbour

This presentation includes forward-looking statements.

Actual results could differ materially from those included in the forward results forward-looking statements looking due to various risk factors and uncertainties including changes in business, economic competitive conditions, regulatory reforms, foreign exchange rate fluctuations and the availability of financing.

These and other risks and uncertainties are detailed in the Company's Annual Report.

M i h/G HQ i i UK US Munich/Germany HQ, sites in UK,

Company

T
h
l
e
c
n
o
o
g
y		 L
d
i
i
H
C
A
L
l
f
t
t
"
e
a
n
g
p
r
o
p
r
e
a
r
y
u
p
a
o
r
m
,
S
&
t
d
i
t
d
t
t
t
t
"
r
o
n
g
u
n
s
p
u
e
p
a
e
n
e
s
a
e
T
h
i
t
e
r
a
p
e
c
u		 O
C
7
0
t
i
b
d
b
d
H
A
L
"
v
e
r
a
n
o
y
p
r
o
g
r
a
m
s
a
s
e
o
n
u
S
t
l
l
i
i
t
h
h
i
"
r
o
n
g
a
a
n
c
e
s
p
a
r
m
a
c
o
m
p
a
n
e
s
w
G
i
i
t
t
i
b
d
t
f
l
i
"
r
o
n
g
p
r
o
p
r
e
a
r
a
n
o
p
o
r
o
o
w
y
y
M
i
l
d
l
i
l
l
t
t
"
e
s
o
n
e
s
a
n
r
o
a
e
s
o
n
a
p
r
o
g
r
a
m
s
y
R
h
h
/
/
e
s
e
a
r
c
D
i
i
t
a
g
n
o
s
c
s		 A
b
D
S
f
f
i
i
b
b
l
l
i
k
t
t
t
t
t
"
e
r
o
e
c
p
p
r
r
o
o
a
a
e
e
o
u
g
r
o
w
n
g
m
a
r
e
,
I
i
i
f
d
i
i
k
t
t
t
t
"
n
c
r
e
a
s
n
g
p
e
n
e
r
a
o
n
o
a
g
n
o
s
c
s
m
a
r
e
F
i
i
l
n
a
n
c
a
s		 S
f
€
9
0
t
i
d
i
t
b
i
l
i
t
i
l
l
i
h
"
u
s
a
n
e
p
r
o
a
y,
m
o
n
c
a
s
f
2
0
0
3
t
d
t
i
i
g
e
n
e
r
a
e
r
o
m
o
p
e
r
a
o
n
s
s
n
c
e

Frankfurt Stock Exchange – TecDAX

An independent antibody company

MorphoSys at a Glance

MorphoSys Announces Clinical Milestone

First of up to Six Expected Clinical Phase 1 Milestones During 2010

M h S AG (FSE MOR P i St d d S t MorphoSys (FSE: MOR; Prime Standard Segment, T DAX ec ) d t d th t it ill ) announced today that it will receive a clinical milestone payment from Centocor Ortho Biotech Inc. (formerly known as: Centocor, Inc.) in connection with the initiation of a phase 1 clinical trial of a HuCALderived antibodyp y in the therapeutic area of inflammatory and autoimmune diseases. The target against which the antibody is directed is undisclosed.

As part of the Centocor Ortho Biotech Inc. collaboration in 2007, a HuCAL antibody became the first from MorphoSys to be developed in two different therapeutic areas – oncology and immunology and in 2009, a different HuCAL antibody advanced in the therapeutic area of inflammation into a phase 1 trial. Today's announcement marks the start of a fourth clinical trial that will be running HuCAL antibodies. Further pre-clinical programs are ongoing.

M h S j t th t i 2010 b t f d i t d ld t li i l MorphoSys projects that in between four and six partnered programs could enter clinical trials. Today's news represents the first HuCAL-derived antibody to achieve this stage during the course of the year. By the end of this year, up to 14 proprietary and partnered antibody programs are expected to be in clinical trials including at least four programs in phase 2 in trials including in 2clinical trials.

Current Product Pipeline: 72 Programs Ongoing

N
a
m
e		 P
t
a
r
n
e
r		 T
t
a
r
g
e		 I
d
i
i
t
n
c
a
o
n		 D
i
s
c
o
v
e
r
y		 P
l
i
i
r
e
c
n
c		 P
h
1
a
s
e		 P
h
2
a
s
e		 P
h
3
a
s
e		 M
k
t
a
r
e
O
M
R
1
0
3		 - G
-C
S
M
F		 R
A
Q
B
H
8
8
0		 No
t
is
va
r		 D
K
K-
1		 Ca
nc
er
C
N
T
O
8
8
8		 Ce
to
n
co
r		 M
C
P-
1		 Im
log
/
m
un
o
y
Ca
nc
er
d.
n.		 No
t
is
va
r		 d.
n.		 d.
n.
Ga
te
b
n
ne
ru
m
a		 Ro
he
c		 β
Am
lo
i
d
y		 A
D
d.
n		 Ce
to
n
co
r		 d.
n		 f
In
la
t
io
m
m
a
n
B
A
Y
7
9-
4
6
2
0		 Sc
Ba
he
ing
y
er
r		 C
(
)
A
I
X
M
N		 Ca
nc
er
d.
n.		 Ce
to
n
co
r		 d.
n.		 f
/
In
la
t
io
A
I
D
m
m
a
n
O
2
0
2
M
R		 - C
3
8
D		 M
l
t
ip
le
M
lo
u
y
e
m
a
2
6
Pa
tn
d
r
er
e
Pr
*
og
ra
m
s		 Va
io
r
us		 Va
io
r
us		 Va
io
*
r
us
3
1
Pa
d
tn
r
er
e
Pr
*
og
ra
m
s		 Va
io
r
us		 Va
io
r
us		 Va
io
*
r
us
M
O
R
1
0
4		 - d.
n.		 In
f
la
t
io
m
m
a
n
M
O
R
1
0
5		 - d.
n.		 In
f
la
t
io
m
m
a
n
M
O
R
2
0
5		 - d.
n.		 Ca
nc
er
O
M
R
2
0
6		 - d.
n.		 Ca
nc
er
d
d.
n.		 O
/
O
M
R
N
V		 d
d.
n.		 d
d.
n.		 L
L
t
te
a		 t
t
N
Ne
s
ws

* Includes cancer, inflammatory, autoimmune, infectious, musculoskeletal & central nervous system diseases n.d. – not disclosed

responders stop responding within 2 years Promising preclinical data for second indication

Current Status:

Significant Potential:

\$10bn

Market

Phase 1 successfully completed

MOR103: Anti-GM-CSF

Primary indication: rheumatoid arthritis

Opportunity in Inflammation

  • Phase 1b/2a trial is ongoing trial
  • Production: PER.C6 ®cell-line (Crucell/DSM)

Intellectual Property:

E l i li t t d US t t i k f tib di Exclusive license to grante US patent covering key uses of antib odies against GM-CSF

Fewer than 25% of RA patients adequately treated; 50% of TNF-

Patent applications covering antibodies & new indications

MOR103 – Ph 1b/2a (MSC-1001) in Rheumatoid Arthritis – Clinical Trial Update

  • Trial approved in Germany, Bulgaria, The Netherlands
  • Study in 135 RA patients, randomized, double-blind, placebo-controlled, multiple ascending dose
  • Geographic mix provides access to full spectrum from biologics-pretreated to biologics-naïve RA patients
  • Primary outcome measures: Adverse event rate and safety profile
  • Secondary outcome measures: DAS28, ACR score set measures and EULAR28 response criteria, cytokines, synovitis, bone edema pharmacokinetics immunogenicity and patient reported edema, pharmacokinetics, and outcomes up to 16 weeks
  • Stable regimen of concomitant RA therapy (including anti-TNFs)
2
0
0
8		 2
0
0
9		 2
0
1
0		 2
0
1
1		 2
0
1
2
P
h
1
P
h
1
b
/
2
a
D
A
l
i
t
a
a
n
a
s
s
y
i
/
F
l
P
h
1
b
2
D
t
n
a
a
a
a

Partnered Discovery Novartis – BHQ880

HuCAL IgG1 antibody, targeting DKK-1

  • Overexpression of DKK-1 by myeloma cells may upset the normal balance between osteoblasts and osteoclasts
  • Antibody vs. DKK-1 may play a role in preventing osteolytic bone disease in multiple m eloma patients yeloma

Phase 1/2 study is ongoing in the US

  • Prec ca s ud es suppo e ypo es s a linical studies support th e hypothesis th at BHQ880 promotes bone formation and thereby inhibits tumor-induced osteolytic disease
  • A phase 1/2 combination study in combination with Zometa/Reclast in relapsed or refractory myeloma patients has started in February 2009
  • Novartis published some early clinical results from this program at the last ASH meeting in the last December 2009 in Orlando

Partnered Discovery Centocor – CNTO888

HuCAL IgG1 antibody targeting MCP-1 (CCL2)

  • Monocyte chemoattractant protein 1 (CCL2) is a recently identified prominent regulator of prostate cancer growth and metastasis (Loberg et al., Cancer Res 2007; 67: (19). October 1, 2007)
  • Recent studies highlight a role for CCL2 in supporting the development of prostate cancer skeletal metastasis

(Li et al Cancer Res 2009; 69: (4) February 15 2009 p 1691) Li al., Res 69: (4). 15, 2009,

Development

  • Currently being developed in two indications
  • Ph 2 i l Phase in oncology
  • Phase 2 in immunology

Recentlyp g resented at ASCO meeting 2010

  • "Utilizing mechanistic PK/PD modeling to simultaneously examine free CCL2, total CCL2, and CNTO 888 serum concentration time data"
  • "Pre-final analysis of first-in-human, first-in-class, phase1 clinical trial of CNTO888 h l l tib d t th CC h ki li d 2 CNTO888, a human monoclonal antibody to the CC-chemokine ligand(CCL2) in patients with advanced solid tumors"

Partnered Discovery Roche – Gantenerumab

HuCAL IgG1 antibody targeting amyloidβ

  • Depolymerizes aggregated A β
  • Crosses blood-brain barrier in transgenic mouse, decreasing cerebral A β burden

Development

  • Two Phase 1 studies completed (single dose arm and multiple ascending dose arm)
  • Mild-to-moderate Alzheimer's patients
  • Randomized double Randomized, double-blind
  • Antibody behaved as expected

Roche plans to move into phase 2 during 2010

Partnered Discovery Additional Programs in Clinical Development

P
t
a
r
n
e
r		 S
t
t
a
s
u
S
d
d
i
l
d
i
l
d
t
t
t
"
u
y
e
a
s
n
o
s
c
o
s
e
/
S
f
0
6
2
0
0
9
t
t
h
1
"
:
a
r
o
p
a
s
e
/
C
f-
f-
0
5
2
0
1
0
l
i
i
l
t
h
i
d
"
n
c
a
p
r
o
o
o
c
o
n
c
e
p
a
c
e
e
:
v
S
t
d
d
t
i
l
t
d
i
l
d
"
u
y
e
a
s
n
o
s
c
o
s
e
0
6
/
2
0
0
9
S
h
1
i
i
f
l
i
t
t
t
"
a
r
p
a
s
e
n
n
a
m
m
a
o
n
:
C
(
)
B
A
Y
7
9
4
6
2
0
t
t
i
A
I
X
M
N
"
a
r
g
e
n
g
-
,
A
i
b
d
d
j
t
t
"
n
o
r
g
c
o
n
g
a
e
y
u
u
-
1
0
/
2
0
0
9
S
h
1
i
l
t
t
"
:
a
r
p
a
s
e
n
o
n
c
o
o
g
y
0
4
/
2
0
1
0
P
P
l
l
i
i
i
i
l
l
d
A
A
C
R
t
t
"
e
:
r
r
e
-c
c
n
n
c
c
a
a
a
a
a
S
t
d
d
t
i
l
t
d
i
l
d
"
e
a
s
n
o
s
c
o
s
e
u
y
0
6
/
2
0
1
0
S
h
1
i
t
t
"
a
r
p
a
s
e
n
:
i
f
l
i
/
i
d
i
t
t
n
a
m
m
a
o
n
a
o
m
m
n
e
s
e
a
s
e
s
u
u

MOR202: Anti-CD 38Opportunity in Multiple Myeloma

Significant Potential:

  • CD38 is a key target to address multiple myeloma therapy due to high expression on multiple myeloma cells
  • Multiple myeloma represents a large commercial opportunity among hematologic cancers
  • Sales of leading therapies in excess of €2.5 billion worldwide

Current Status:

  • MOR202 demonstrates the ability to kill myeloma cells in vitro and across multiple preclinical in vivo models
  • Non-clinical safety y pp and efficacy data support the initiation of clinical studies
2
0
0
9		 2
0
1
0		 2
0
1
1
f
i
M
t
a
n
u
a
c
u
r
n
g
S
S
T
T
i
i
i
i
d
d
t
t
t
t
o
c
x
y
u
y
C
i
T
A
P
t
r
e
p
a
r
a
o
n
C
T
A
F
i
l
i
n
g
S
f
P
h
/
1
2
t
t
a
r
o
a

1510Phase 5 1 Phase 2 5 1 9 402005 2006 2007 2008 2009 2010E 1 2 444

Number of Partnered and Proprietary Programs at Year-end

Cli i l A tib d Pi li i K Vl D i ClinicalAntibody Pipeline is a Key Value Driver

Current Pipeline: Projected HuCAL Drugs on the Market

Source: MorphoSys internal statistics & Tufts Centre for the Study of Drug Development

AbD Serotec: Promising Market Opportunities

  • Potential for HuCAL technology in delivering truly differentiated diagnostic products
  • Growing importance of diagnostics in pharmaceutical development
  • Synergies with therapeutic area
  • Revenue g pp y rowth in 2010 of approximately 10%
  • Operating margin 5% 8%

MorphoSys AG – Company Update – June 2010 © MorphoSys AG MorphoSys Page 19

Guidance 2010

I
i
l
l
i
E
U
R
n
m
o
n		 2
0
1
0
E
*		 2
0
0
9
A
T
l
G
R
t
o
a
r
o
u
p
e
v
e
n
u
e
s		 8
9
9
3
–		 8
1
0.
S
A
b
D
t
e
r
o
e
c		 2
1
2
2
–		 1
9
4
G
O
i
P
f
i
t
t
r
o
u
p
p
e
r
a
n
g
r
o		 5
9
–		 1
1.
4
S
O
f
A
b
D
t
t
i
P
i
t
M
i
e
r
o
e
c
p
e
r
a
n
g
r
o
a
r
g
n		 %
%
5
8
–		 %
5
*
Es
t
im
te
d n
be
a
um
rs

Increase of total proprietary R&D investment to € 26 29 million (2009: € 19 3 million) 19.3

2011 – 2012

  • Aiming for 10% - 20% annual revenue growth
  • Maintain profitability while strengthening pipeline

Shareholder Structure and Key Financials

Key Financials

M
&
t
a
n
a
g
e
m
e
n		 Q
1
2
0
1
0		 Q
1
2
0
0
9
%
7
S
i
B
d
u
p
e
r
v
s
o
r
y
o
a
r
5
%		 R
e
e
n
e
s
v
u		 2
0.
6		 1
9.
1
%
2		 C
f
G
S
t
d
l
d
o
s
o
o
o
s
o		 1.
7		 1.
7
1
0
%		 R
&
D
E
p
e
n
s
e
s
x		 9
3		 8
5
S
G
&
A
E
x
p
e
n
s
e
s
,		 4
9		 4
8
7
%		 i
T
l
O
E
t
t
o
a
p
e
r
a
n
g
x
p
e
n
s
e
s		 1
5.
9		 1
4.
9
7
%		 O
i
P
f
i
t
t
p
e
r
a
n
g
r
o		 4.
7		 4.
2
4
%
4
%
7
%		 f
i
N
P
t
t
e
r
o		 3.
2		 3.
5

Cash, Cash Equivalents and Available-for-sale Financial Assets as of March 31, 2010:

€ 147.3 million

Forthcoming Events

  • Additional clinical data from partnered programs
  • More clinical starts
  • At least one additional phase 2
  • 4 – 6 new INDs
  • MOR202 Fil li i l t i l li ti i Q4 2010 MOR202: File clinical trial application in 2010
  • Strengthen portfolio: New projects, including co-development
  • Technology: Update regarding latest technology developments
  • Potential strategic transactions
  • In-licensing to strengthen portfolio
  • Strengthen technology platform
  • Broaden offering in the diagnostic space (AbD Serotec)

Future Value Creation

Thank You.

www.morphosys.com

Dr. Simon Moroney

Chief Executive Officer

Phone +49 (0)89 / 899 27-311 Fax +49 (0)89 / 899 27-5311 Email [email protected] Dr. Claudia Gutjahr-Löser Head of Corporate Communications & IR

Phone +49 (0)89 / 899 27-122 Fax +49 (0)89 / 899 27-5122 Email [email protected]

HuCAL®, HuCAL GOLD®, HuCAL PLATINUM®, CysDisplay®, RapMAT® and AutoCAL® are registered trademarks of MorphoSys AG

More from MorphoSys AG

AGM Information 2024
Aug 27
Delisting Announcement 2024
Aug 5
AGM Information 2024
Jul 19
AGM Information 2024
Jul 19
Declaration of Voting Results & Voting Rights Announcements 2024
Jul 18
Delisting Announcement 2024
Jul 12
Legal Proceedings Report 2024
Jul 12
Report Publication Announcement 2024
Jul 5
Major Shareholding Notification 2024
Jul 2
Declaration of Voting Results & Voting Rights Announcements 2024
Jun 21
View all filings →